Literature DB >> 28846472

The current state of food allergy therapeutics.

Meng Chen1, Michael Land2.   

Abstract

The prevalence of IgE mediated food allergy is an increasing public health concern. The current standard of treatment is strict avoidance of the offending food(s). There are no FDA approved treatments for food allergy. This review will provide an overview of strategies currently under investigation for the treatment of food allergy. The main focus of research has been directed at various forms of immunotherapy, including oral, sublingual and epicutaneous delivery routes. While oral immunotherapy (OIT) has shown the greatest promise for efficacy in terms of amount of protein that can be ingested, it has also demonstrated less tolerability and a less favorable safety profile as compared to sublingual immunotherapy (SLIT) and epicutaneous immunotherapy (EPIT), which offers the least protection but has the best safety and tolerability profile. Investigation is also underway for modified antigens that may be used for immunotherapy and for adjuncts that may help facilitate immunotherapy, including biologics such as anti-IgE therapy, and also probiotics. There are also a number of preclinical concepts that are being evaluated to manipulate the antigens and/or the immune system that may one day be translatable to patients.

Entities:  

Keywords:  epicutaneous immunotherapy; food allergy; modified food allergens; omalizumab; oral immunotherapy; sublingual immunotherapy; traditional chinese medicine

Mesh:

Substances:

Year:  2017        PMID: 28846472      PMCID: PMC5647972          DOI: 10.1080/21645515.2017.1359363

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  69 in total

1.  The safety and efficacy of sublingual and oral immunotherapy for milk allergy.

Authors:  Corinne A Keet; Pamela A Frischmeyer-Guerrerio; Ananth Thyagarajan; John T Schroeder; Robert G Hamilton; Stephen Boden; Pamela Steele; Sarah Driggers; A Wesley Burks; Robert A Wood
Journal:  J Allergy Clin Immunol       Date:  2011-11-30       Impact factor: 10.793

2.  Specific oral tolerance induction in children with very severe cow's milk-induced reactions.

Authors:  Giorgio Longo; Egidio Barbi; Irene Berti; Rosanna Meneghetti; Angela Pittalis; Luca Ronfani; Alessandro Ventura
Journal:  J Allergy Clin Immunol       Date:  2007-12-26       Impact factor: 10.793

3.  A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy.

Authors:  Hugh A Sampson; Donald Y M Leung; A Wesley Burks; Gideon Lack; Sami L Bahna; Stacie M Jones; Dennis A Wong
Journal:  J Allergy Clin Immunol       Date:  2011-03-11       Impact factor: 10.793

Review 4.  Potential treatments for food allergy.

Authors:  Stephanie Albin; Anna Nowak-Węgrzyn
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

5.  Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model.

Authors:  Xiu-Min Li; Kamal Srivastava; James W Huleatt; Kim Bottomly; A Wesley Burks; Hugh A Sampson
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

6.  Dietary baked milk accelerates the resolution of cow's milk allergy in children.

Authors:  Jennifer S Kim; Anna Nowak-Węgrzyn; Scott H Sicherer; Sally Noone; Erin L Moshier; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2011-05-23       Impact factor: 10.793

7.  Administration of a probiotic with peanut oral immunotherapy: A randomized trial.

Authors:  Mimi L K Tang; Anne-Louise Ponsonby; Francesca Orsini; Dean Tey; Marnie Robinson; Ee Lyn Su; Paul Licciardi; Wesley Burks; Susan Donath
Journal:  J Allergy Clin Immunol       Date:  2015-01-13       Impact factor: 10.793

8.  Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy.

Authors:  Kamal D Srivastava; Alyssa Siefert; Tarek M Fahmy; Michael J Caplan; Xiu-Min Li; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2016-04-26       Impact factor: 10.793

Review 9.  Advances in food allergy oral immunotherapy: toward tolerance.

Authors:  Deborah M Hussey Freeland; Hua Fan-Minogue; Jonathan M Spergel; Talal A Chatila; Kari C Nadeau
Journal:  Curr Opin Immunol       Date:  2016-10-13       Impact factor: 7.486

10.  Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab.

Authors:  Philippe Bégin; Tina Dominguez; Shruti P Wilson; Liane Bacal; Anjuli Mehrotra; Bethany Kausch; Anthony Trela; Morvarid Tavassoli; Elisabeth Hoyte; Gerri O'Riordan; Alanna Blakemore; Scott Seki; Robert G Hamilton; Kari C Nadeau
Journal:  Allergy Asthma Clin Immunol       Date:  2014-02-20       Impact factor: 3.406

View more
  5 in total

Review 1.  Clinical Manifestations of Pediatric Food Allergy: a Contemporary Review.

Authors:  Ling-Jen Wang; Shu-Chi Mu; Ming-I Lin; Tseng-Chen Sung; Bor-Luen Chiang; Cheng-Hui Lin
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-14       Impact factor: 8.667

2.  Polymorphic Variants of Interleukin-13 R130Q and Interleukin-4 T589C in Children with and without Cow's Milk Allergy.

Authors:  Oksana Matsyura; Lesya Besh; Olena Kens; Dana Kosorinová; Katarína Volkovová; Sandor G Vari
Journal:  Life (Basel)       Date:  2022-04-19

3.  Broad perspectives of allergen specific immunotherapy.

Authors:  Wayne Robert Thomas
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

Review 4.  Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.

Authors:  Gregorio Gomez
Journal:  Front Immunol       Date:  2019-02-07       Impact factor: 7.561

Review 5.  Therapeutic perspectives in food allergy.

Authors:  Francesco Marcucci; Chiara Isidori; Alberto Argentiero; Cosimo Neglia; Susanna Esposito
Journal:  J Transl Med       Date:  2020-08-05       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.